Gene Polymorphisms and the Bone Mineral Density Response to Alendronate Therapy in Postmenopausal Chinese Women with Low Bone Mass

Overview

Journal Pharmgenomics Pers Med

Publisher Dove Medical Press

Date 2022 Jan 7

PMID 34992429

Citations 1

Authors

Jiao Zhao

Li Liu

Shanshan Lv

Chun Wang

Hua Yue

Zhenlin Zhang

Affiliations

Soon will be listed here.

Abstract

Purpose: Alendronate is a widely used anti-osteoporotic drug. gene is a newly identified early-onset Paget's disease pathogenic gene. The purpose of this study is to study whether the genetic variations in this gene affect the clinical efficacy of alendronate in postmenopausal Chinese women with low bone mass.

Patients And Methods: Seven single nucleotide polymorphisms in gene were genotyped. A total of 500 postmenopausal women with osteoporosis or osteopenia were included. All participants were treated with weekly alendronate 70 mg for 12 months. A total of 466 subjects completed the follow-up. Bone mineral density (BMD) of lumbar spine, femoral neck and total hip were measured at baseline and after treatment.

Results: After 12 months of treatment, the BMD of lumbar spine, femoral neck and total hip all increased significantly (all < 0.001), with an average increase of 4.72 ± 5.31%, 2.08 ± 4.45%, and 2.42 ± 3.46%, respectively. At baseline, there were no significant differences in BMD at lumbar spine, femoral neck and total hip between different genotype groups ( > 0.05). We failed to identify any significant association between the genotypes or haplotypes of and the BMD response to alendronate therapy.

Conclusion: Genetic polymorphisms of may not be a major contributor to the therapeutic response to alendronate treatment in Chinese women with low bone mass.

Citing Articles

Association of PFN1 Gene Polymorphisms with Bone Mineral Density, Bone Turnover Markers, and Osteoporotic Fractures in Chinese Population.

Wu Y, Wu S, Yang E, Zhang G, Shi Q, Liang J Calcif Tissue Int. 2023; 113(2):207-215.

PMID: 37401976 DOI: 10.1007/s00223-023-01102-2.

References

Marini F, Falchetti A, Silvestri S, Bagger Y, Luzi E, Tanini A . Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis. Curr Med Res Opin. 2008; 24(9):2609-15. DOI: 10.1185/03007990802352894. View

Liu Y, Liu H, Li M, Zhou P, Xing X, Xia W . Association of farnesyl diphosphate synthase polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis. Chin Med J (Engl). 2014; 127(4):662-8. View

Eisman J . Pharmacogenetics of the vitamin D receptor and osteoporosis. Drug Metab Dispos. 2001; 29(4 Pt 2):505-12. View

Boopathy S, Silvas T, Tischbein M, Jansen S, Shandilya S, Zitzewitz J . Structural basis for mutation-induced destabilization of profilin 1 in ALS. Proc Natl Acad Sci U S A. 2015; 112(26):7984-9. PMC: 4491777. DOI: 10.1073/pnas.1424108112. View

Seeman E, Bianchi G, Khosla S, Kanis J, Orwoll E . Bone fragility in men--where are we?. Osteoporos Int. 2006; 17(11):1577-83. DOI: 10.1007/s00198-006-0160-8. View

Cummings S, Black D, Thompson D, Applegate W, Barrett-Connor E, Musliner T . Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1999; 280(24):2077-82. DOI: 10.1001/jama.280.24.2077. View

Dawson-Hughes B . A revised clinician's guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab. 2008; 93(7):2463-5. DOI: 10.1210/jc.2008-0926. View

Lima C, Javorski N, Souza A, Barbosa A, Valenca A, Crovella S . Polymorphisms in key bone modulator cytokines genes influence bisphosphonates therapy in postmenopausal women. Inflammopharmacology. 2017; 25(2):191-201. DOI: 10.1007/s10787-017-0322-7. View

Qureshi A, Herd R, Blake G, Fogelman I, Ralston S . COLIA1 Sp1 polymorphism predicts response of femoral neck bone density to cyclical etidronate therapy. Calcif Tissue Int. 2002; 70(3):158-63. DOI: 10.1007/s00223-001-1035-9. View

10.

Nguyen T, Blangero J, Eisman J . Genetic epidemiological approaches to the search for osteoporosis genes. J Bone Miner Res. 2000; 15(3):392-401. DOI: 10.1359/jbmr.2000.15.3.392. View

11.

Camacho P, Petak S, Binkley N, Diab D, Eldeiry L, Farooki A . AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE . Endocr Pract. 2020; 26(5):564-570. DOI: 10.4158/GL-2020-0524. View

12.

Witke W, Podtelejnikov A, Nardo A, Sutherland J, Gurniak C, Dotti C . In mouse brain profilin I and profilin II associate with regulators of the endocytic pathway and actin assembly. EMBO J. 1998; 17(4):967-76. PMC: 1170446. DOI: 10.1093/emboj/17.4.967. View

13.

Gao C, Xu Y, Li L, Gu W, Yi C, Zhu Q . Prevalence of osteoporotic vertebral fracture among community-dwelling elderly in Shanghai. Chin Med J (Engl). 2019; 132(14):1749-1751. PMC: 6759100. DOI: 10.1097/CM9.0000000000000332. View

14.

Coffin J, Homer-Bouthiette C, Hurley M . Fibroblast Growth Factor 2 and Its Receptors in Bone Biology and Disease. J Endocr Soc. 2018; 2(7):657-671. PMC: 6009610. DOI: 10.1210/js.2018-00105. View

15.

Ogawa S, Ouchi Y . [Therapeutic purpose and treatment guideline of osteoporosis]. Clin Calcium. 2012; 22(6):885-9. DOI: CliCa1206885889. View

16.

Wang C, Zheng H, He J, Zhang H, Yue H, Hu W . Genetic polymorphisms in the mevalonate pathway affect the therapeutic response to alendronate treatment in postmenopausal Chinese women with low bone mineral density. Pharmacogenomics J. 2014; 15(2):158-64. DOI: 10.1038/tpj.2014.52. View

17.

Zaidi A, Manna S . Profilin-PTEN interaction suppresses NF-κB activation via inhibition of IKK phosphorylation. Biochem J. 2016; 473(7):859-72. DOI: 10.1042/BJ20150624. View

18.

Hein M, Hubner N, Poser I, Cox J, Nagaraj N, Toyoda Y . A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell. 2015; 163(3):712-23. DOI: 10.1016/j.cell.2015.09.053. View

19.

Merlotti D, Materozzi M, Bianciardi S, Guarnieri V, Rendina D, Volterrani L . Mutation of PFN1 Gene in an Early Onset, Polyostotic Paget-like Disease. J Clin Endocrinol Metab. 2020; 105(8). DOI: 10.1210/clinem/dgaa252. View

20.

Kanis J, Burlet N, Cooper C, Delmas P, Reginster J, Borgstrom F . European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008; 19(4):399-428. PMC: 2613968. DOI: 10.1007/s00198-008-0560-z. View